1 COVID-19 Vaccination in Pregnancy: The

Impact of Multimorbidity and Smoking Status

- on Vaccine Hesitancy, a Cohort Study of
- ⁴ 25,111 Women in Wales, UK.
- 5 Mhereeg M¹, Jones H¹, Kennedy J¹, Seaborne M¹, Parker M¹, Kennedy N¹, Akbari A²,
- 6 Zuccolo L³, Azcoaga-Lorenzo A⁴, Davies A⁵, Nirantharakumar K⁶, Brophy S¹
- 7

```
8 Affiliations:
```

- 9 ¹National Centre for Population Health and Wellbeing Research, Swansea University
- 10 Medical School, Faculty of Medicine, Health and Life Science, Swansea, Wales, UK.
- ¹¹ ²Population Data Science, Swansea University Medical School, Faculty of Medicine, Health
- 12 and Life Science, Swansea, Wales, UK
- 13 ³Health Data Science Centre, Fondazione Human Technopole, Milan, Italy
- ⁴School of Medicine, University of St Andrews, Scotland, UK and Hospital Rey Juan Carlos.
- 15 Instituto de Investigación Sanitaria Fundación Jimenez Diaz. Madrid. Spain.
- ⁵Research and Evaluation Division, Public Health Wales, UK.
- ⁶Institute of Applied Health Research, Birmingham University, Birmingham, UK.
- 18
- 19 Corresponding author: m.r.mhereeg@swansea.ac.uk
- 20
- 21

It is made available under a CC-BY-NC-ND 4.0 International license .

22 Abstract

23 Background

Multimorbidity and pregnancy are two risk factors for more severe outcomes after a SARS-CoV-2 infection, thus vaccination uptake is important for pregnant women living with multimorbidity. This study aimed to examine the impact of multimorbidity, smoking status, and demographics (age, ethnic group, area of deprivation) on vaccine hesitancy among pregnant women in Wales using electronic health records (EHR) linkage.

30 Methods

31 This cohort study utilised routinely collected, individual-level, anonymised population-32 scale linked data within the Secure Anonymised Information Linkage (SAIL) Databank. Pregnant women were identified from 13th April 2021 to 31st December 33 34 2021. Survival analysis was utilised to examine and compare the length of time to 35 vaccination uptake in pregnancy by multimorbidity and smoking status, as well as 36 depression, diabetes, asthma, and cardiovascular conditions independently. Variation in uptake by; multimorbidity, smoking status, and demographics was 37 38 examined jointly and separately for the independent conditions using hazard ratios 39 (HR) from the Cox regression model. A bootstrapping internal validation was 40 conducted to assess the performance of the models.

41 Results

42 Within the population cohort, 8,203 (32.7%) received at least one dose of the 43 COVID-19 vaccine during pregnancy, with 8,572 (34.1%) remaining unvaccinated

It is made available under a CC-BY-NC-ND 4.0 International license .

44 throughout the follow-up period, and 8,336 (33.2%) receiving the vaccine 45 postpartum. Women aged 30 years or older were more likely to have the vaccine in pregnancy. Those who had depression were slightly but significantly more likely to 46 47 have the vaccine compared to those without depression (HR = 1.08, 95% CI 1.03 to 48 1.14, p = 0.02). Women living with multimorbidity (> 1 health condition) were 1.12 49 times more likely to have the vaccine compared to those living without multimorbidity 50 (HR = 1.12, 95% CI 1.04 to 1.19, p = 0.001). Vaccine uptakes were significantly 51 lower among both current smokers and former smokers compared to never smokers 52 $(HR = 0.87, 95\% \text{ CI } 0.81 \text{ to } 0.94, p < 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.85 \text{ to } 0.98, p = 0.001 \text{ and } HR = 0.92, 95\% \text{ CI } 0.95\% \text{ cI$ 53 0.015 respectively). Uptake was also lower among those living in the most deprived 54 areas compared to those living in the most affluent areas (HR = 0.89, 95% CI 0.83 to 55 0.96, p = 0.002). The validated model had similar performance and revealed that 56 multimorbidity, smoking status, age, and deprivation level together have a significant 57 impact on vaccine hesitancy (p < 0.05 for all).

58 Conclusion

Younger women, living without multimorbidity (zero or only one health condition), current and former smokers, and those living in the more deprived areas are less likely to have the vaccine, thus, a targeted approach to vaccinations may be required for these groups. Women living with multimorbidity are slightly but significantly less likely to be hesitant about COVID-19 vaccination when pregnant.

64 **keywords:** COVID-19 vaccination, pregnancy, vaccine uptake, vaccine hesitancy, SAIL.

It is made available under a CC-BY-NC-ND 4.0 International license .

65 Background

66 COVID-19 vaccination is recognised as a successful public health measure [1], and 67 national vaccine strategies were implemented during the COVID-19 pandemic. 68 However, an increasing number of the general population perceive vaccinations as 69 dangerous and not needed [1]. Vaccine hesitancy may be more prevalent in different 70 populations [2]. For example, vaccine hesitancy may be more common in pregnant 71 women as they have additional concerns [3]. During the COVID-19 pandemic, the 72 limited data and changes in advice and recommendations regarding vaccination in 73 pregnancy inevitably led to some hesitancy towards being vaccinated among 74 pregnant women [4]. Despite increasing evidence that COVID-19 vaccines are safe 75 and effective for pregnant women, vaccine hesitancy remains high [5].

76 Research is limited on population-level COVID-19 vaccine uptake in pregnancy in 77 the UK. However, in Scotland, a national, prospective cohort study identifying ongoing pregnancies through extensive electronic health records (EHR) linkages 78 79 showed vaccination rates in pregnant women to be considerably lower than in the 80 general population; 32.3% in pregnant women compared to 77.4% in all women [6]. 81 In England, 22.7% of women giving birth in August 2021 had received at least one 82 dose of vaccine. This increased to 32.3% of women who gave birth in September 83 and rose again to 53.7% in December 2021 [7]. In Wales, a mixed methods study 84 utilising routinely collected linked data from the Secure Anonymised Information 85 Linkage (SAIL) Databank and the Born In Wales Birth Cohort found that only 1 in 3 86 pregnant women would have the COVID-19 vaccine during pregnancy, even though 87 2 in 3 reported they would have the vaccination [5]. Despite the overall increase in

It is made available under a CC-BY-NC-ND 4.0 International license .

coverage, the uptake remains lower amongst pregnant women compared to thegeneral population of the same age group [7].

90 Various factors may influence vaccine acceptance or refusal. Multimorbidity is 91 defined as the co-occurrence of two or more long-term health conditions, which can 92 include defined physical and mental health conditions such as diabetes, depression, 93 asthma, and cardiovascular diseases [8]. Long-term health conditions are those that 94 generally last a year or longer and have a significant impact on a person's life [9]. In 95 the United Kingdom (UK), the COVID-19 pandemic has affected expectant mothers' 96 mental health by increasing the prevalence of depression by 47% [10]. Research has 97 found that having pre-existing illnesses or multimorbidity is associated with a lower 98 rate of vaccine refusal [11,12].

99 Health related behaviours may influence vaccine acceptance, such as smoking 100 habits. Smoking status includes the categories of current smoker, former smoker, 101 never smoked, or smoking status unknown. The differences in negative attitudes 102 towards vaccines in general and intentions to vaccinate against COVID-19, 103 specifically by smoking status, has been examined in a sample of adults in the UK 104 [13]. Relative to never smoked and former smokers, current smokers reported 105 significantly higher mistrust of vaccines and any benefits, were more worried about 106 negative future effects, and had a stronger preference for natural immunity. With a 107 high number of smokers belonging to socially clustered and disadvantaged 108 socioeconomic groups, lower vaccine uptake in this group could also heighten health 109 inequalities [13].

110 The determinants of vaccine hesitancy have been explored previously, aiming to 111 create targeted interventions for the most at-risk groups. From 1,203 young adults

It is made available under a CC-BY-NC-ND 4.0 International license .

112 aged 18-25 in the United States, vaccine hesitancy was significantly higher among 113 young adults who were current smokers (including electronic cigarettes) when 114 compared to non-current smokers (36% vs. 22%) [14]. Moreover, multivariable 115 regression analysis demonstrated that current smokers, compared to non-current 116 smokers, had more than two times the odds of reporting COVID-19 vaccine 117 hesitancy [14]. In a similar study, the prevalence of COVID-19 vaccine hesitancy in 118 the UK was analysed, which reported again that vaccine hesitancy was higher in 119 younger age groups (26.5% in 16–24-year-olds compared to 4.5% in ages 75+) [15]. 120 Vaccine acceptance also varied between ethnic groups. Vaccine hesitancy was 121 higher in Black (71.8%) and Pakistani or Bangladeshi (42.3%) ethnic groups and 122 lowest in the White British or Irish group (15.6%) [15].

The Office for National Statistics (ONS) investigated hesitancy towards the COVID-19 vaccine based on the Opinions and Lifestyle Survey (OPN) covering the period from 23rd June to 18th July 2021. It was reported that adults living in the most deprived areas of England (based on the Index of Multiple Deprivation) were more likely to report vaccine hesitancy (8%) than adults living in the least deprived areas (2%) [16].

The current study aims to examine the impact of multimorbidity, smoking status, and demographics (age, ethnic group, area of deprivation) on vaccine hesitancy among pregnant women in Wales using electronic health records (EHR) linkage. Identifying groups with higher vaccine hesitancy is critical to develop targeted interventions to enhance vaccine uptake rates.

It is made available under a CC-BY-NC-ND 4.0 International license .

134 Methods

135 Study design and setting

A cohort study utilising routinely collected individual-level, anonymised populationscale linked data within the Secure Anonymised Information Linkage (SAIL) Databank. Data sources include general practitioners (GP), hospital admissions, national community child health, maternal indicators, and vaccination data sources. All women recorded as being pregnant on or after 13th April 2021, aged 18 years or older, and eligible for COVID-19 vaccination were identified. They were linked to the COVID-19 vaccination data for dates up to and including 31st December 2021.

143 Data sources and linkage

144 Analysis was undertaken using anonymised population-scale, individual-level linked 145 routinely collected national-scale data available in the SAIL Databank [17,18], which 146 anonymously links a wide range of person-based data employing a unique personal 147 identifier. The linkage includes primary care data (from Wales Longitudinal General 148 Practice (WLGP)) linked with secondary care data (from inpatient hospital 149 admissions, inpatient from Patient Episode Database for Wales (PEDW) and 150 outpatient from Outpatient Database for Wales (OPDW)), pregnancy and maternity 151 related data (from the National Community Child Health (NCCH) and Maternal 152 Indicators (MIDS)) and vaccination data (from the COVID-19 Vaccination Dataset 153 (CVVD)). The primary care data utilises Read codes, which are predominantly 5-digit 154 codes that relate to diagnosis, medication, and process of care codes. The 155 secondary care data uses International Classification of Diseases version 10 (ICD-10) codes for diagnosis and OPCS Classification of Interventions and Procedures 156

medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283200; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

157 version 4 (OPCS-4) surgical interventions. The NCCH comprises information 158 pertaining to birth registration, monitoring of child health examinations, and 159 immunisations. The MIDS data contains data relating to the woman at initial 160 assessment and to the mother and baby (or babies) for all births. In addition to these 161 data sources, the Welsh Demographic Service Dataset (WDSD) was linked to 162 extract Lower-layer Super Output Area (LSOA) version 2011 information associated 163 with area-level deprivation. In particular, the Welsh Index for Multiple Deprivation 164 (WIMD) version 2019 was employed as a proxy to assess socioeconomic status. 165 These records were linked at the individual level for all women known to be pregnant in Wales between 13th April 2021 and 31st December 2021. Linkage quality has been 166 167 assessed and reported as 99.9% for WLGP records and 99.3% for PEDW records 168 [19]. All linkage was at the individual level.

169 Study population and key dates

170 Pregnant women were identified as any woman who had pregnancy codes in the 171 WLGP data, in hospital admissions (PEDW) for pregnancy, or mothers in the NCCH 172 or MIDS data with the baby birth date (Pregnancy end date) and gestational age at 173 birth available. The baby's birth date and gestational age enabled the start date of 174 pregnancy to be determined for those who gave birth during the study period. Data 175 collected included vaccination data, maternal age, ethnic group, WIMD 2019, 176 smoking status, depression, diabetes, asthma, and cardiovascular disease. The 177 WIMD 2019 is an official measure for the relative deprivation of areas of Wales. It 178 combines eight separate domains of deprivation, each compiled from a range of 179 different indicators (income, employment, health, education, access to services, 180 housing, community safety, and physical environment) into a single score and is

It is made available under a CC-BY-NC-ND 4.0 International license .

widely utilised to measure deprivation in Wales. Ethnic groups are categorised in SAIL into White, Asian, Mixed, Black, and Other. Smoking status is categorised in SAIL into Current Smoker, Former Smoker, Never Smoker, and Unknown [22]. In cases where women had multiple recorded statuses, the most recent status during or prior to pregnancy was selected.

The study start date of 13th April 2021 was selected because phase 2 of the 186 187 vaccination program, which aimed to provide vaccinations to individuals aged 40 to 188 49, 30 to 39, and 18 to 29 years, commenced on this date. The inclusion criteria 189 were currently pregnant women who had not received the vaccination or had one 190 dose of vaccination before pregnancy, alive, known pregnant on the first day of 191 follow-up, and aged 18 years or older. The exclusion criteria were women who were 192 fully vaccinated (i.e. two vaccinations) before pregnancy, those for whom it was not 193 possible to determine the start date of pregnancy due to unavailability of the 194 gestational age and initial assessment dates in their records or those with 195 miscarriage or stillbirth outcomes. Currently, within SAIL researchers are unable to 196 account for terminations as these are classed as sensitive data and not currently 197 accessible for research purposes.

198 Calculating pregnancy start date

199 Pregnancy start dates were calculated from the following sources:

For pregnancies identified from the NCCH and MIDS data, the pregnancy start dates were calculated based on the gestational age and the week of birth data items available in these data sources. In cases where gestational age is missing, a value of 40 weeks was applied as the majority of those with missing data (92%) had birth weights suggestive of full-term infants. Thus, the pregnancy start date (last

It is made available under a CC-BY-NC-ND 4.0 International license .

205 menstrual period) was simply calculated by subtracting the gestational age at birth 206 (in weeks) from the week of birth. Pregnancies identified from both data sources 207 were compared/matched and duplicate records were removed.

208 For pregnancies identified from the WLGP data, all pregnant women with a 209 pregnancy code and event date that occurred during the study period were extracted 210 (Supplementary Table 1). For those identified from the hospital admissions data 211 (PEDW), all women with a pregnancy diagnosis code and an attendance date 212 occurring during the study period were also extracted (Supplementary Table 2). 213 Identified cases from both the WLGP and PEDW were separately matched to those 214 identified from the NCCH and MIDS data to include only those who are still pregnant. 215 Furthermore, the identified cases from both resources were further matched to 216 remove duplicates and then linked to the initial assessment-related data items in the 217 MIDS data. The gestational age in weeks and initial assessment data items are 218 available in order to calculate the pregnancy start date. In cases where multiple 219 records were found per pregnant woman, only the first occurring record between the 220 study dates of interest was selected. The pregnancy start date for every successfully 221 linked case was then calculated by subtracting the gestational age from the initial 222 assessment date.

223 Multimorbidity in pregnancy

Multimorbidity was defined by the presence of two or more long-term health conditions, which can include defined physical and mental health conditions [8]. Long-term health conditions are those that generally last a year or longer and have a significant impact on a person's life [9]. Four long-term health conditions including depression, diabetes, asthma, and cardiovascular were selected on the following

medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283200; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

229 basis: (1) prevalence; (2) potential to impact vaccine uptake; and (3) recorded in the 230 study datasets. These conditions were aggregated to generate a new multimorbidity 231 variable with two distinct categories: Multimorbid and Non-multimorbid. The 232 Multimorbid category comprises those with two or more health conditions, while the 233 Non-multimorbid comprises healthy individuals together with those with only one 234 health condition. Read codes for depression, diabetes, asthma, and cardiovascular 235 can be found in Supplementary Tables 3 to 6 respectively. ICD-10 codes for the 236 same conditions can be found in Supplementary Tables 7 to 10 respectively.

237 Statistical analysis

238 Kaplan-Meier survival analysis was employed to examine time to vaccination by 239 depression, diabetes, asthma, and cardiovascular diseases independently, by 240 multimorbidity, as well as by smoking status censored at the birth, death, or moved 241 out of Wales while pregnant. The Log Rank test was used to determine if there were 242 differences in the survival distributions of vaccine uptake times within the diseases 243 independently, multimorbidity, and smoking status. Differences were reported in 244 median times (MD) with 95% confidence intervals and significance level accepted at 245 p<0.05. Multivariate Cox regression hazard models were utilised to examine the 246 impact of depression, diabetes, asthma, and cardiovascular diseases on vaccine 247 acceptance independently with age group, ethnic group, area of deprivation, and 248 smoking status incorporated into the model, as well as the impact of multimorbidity, 249 age group, ethnic group, area of deprivation, and smoking status on vaccine 250 acceptance, reporting hazard ratios (HR) with 95% confidence intervals and 251 significance level accepted at p<0.05. Bootstrapping internal validation was 252 conducted to assess the performance of the model, reporting bootstrapped Beta

It is made available under a CC-BY-NC-ND 4.0 International license .

253 coefficients (B), standard error, 95% confidence intervals, and significance level 254 accepted at p<0.05. The reference groups were those without multimorbidity, never 255 smokers, aged 25-29, white ethnic group, and those living in the most affluent area. 256 The data handling and preparation for the descriptive statistics, survival analysis, 257 and Cox proportional hazard modelling were performed in an SQL IBM DB2 258 database within the SAIL Databank utilising Eclipse software. Final data preparation 259 specific to these analyses, such as setting the reference groups was performed in 260 IBM SPSS Statistics 28. Descriptive statistics, Survival, and Cox regression analyses 261 were performed in SPSS.

262 **Results**

A total of 28.343 pregnant women were identified from 13th April 2021 through 31st 263 264 December 2021. After excluding women who were fully vaccinated before pregnancy 265 (n=3,232), the cohort comprised 25,111 pregnant women. Those women were 266 followed up, and their records were linked to the COVID-19 vaccination data up to 267 and including 31st December 2021. Over the study period, 8,203 (32.7%) of pregnant 268 women received at least one dose of the COVID-19 vaccine during pregnancy, 8,572 269 (34.1%) were not vaccinated, and 8,336 (33.2%) received the vaccine after giving 270 birth (Figure 1 describes the participants in the cohort). Most of the women were 271 aged between 30-39, and between 25-29 years (48.4% and 29.7% respectively). 272 The majority were White (77.8%). Nearly a quarter were living in the most deprived 273 quintile (23.3%) and 14.4% were in the least deprived quintile. 29.5% of women were 274 diagnosed with depression, 5.8% had diabetes, 23.9% had Asthma, 3.3% had 275 cardiovascular, and 12.9% had two or more health conditions (Table 1).

Fig. 1. Flowchart of the cohort identification.

It is made available under a CC-BY-NC-ND 4.0 International license .



277

278 Table 1. Descriptive summaries of the pregnant women eligible for vaccination

		Ν	%
•	18-24	4,664	18.6
Age group	25-29	7,447	29.7
	30-39	12,143	48.4
	40-50	857	3.4
	White ¹	19,547	77.8
Ethnic group	Asian ²	902	3.6
	Mixed ³	316	1.3
	Black ⁴	440	1.8
	Other ⁵	571	2.3
	Unknown	3,335	13.3
	1 st (Most deprived)	5,840	23.3
wimd Quintile 2019	2 nd	4,795	19.1
	3 rd	4,157	16.6
	4 th	3,804	15.1
	5 th (Least deprived)	3,626	14.4

It is made available under a CC-BY-NC-ND 4.0 International license .

	Unknown	2,889	11.5
Smoking Status	Current smoker	4,441	17.1
	Former smoker	3,150	12.5
	Never smoker	12,418	49.5
	Unknown	5,102	20.3
Depression	Yes	7,419	29.5
	No	17,692	70.5
Diabetes	Yes	1,468	5.8
	No	23,643	94.2
Asthma	Yes	5,999	23.9
	No	19,112	76.1
Cardiovascular	Yes	826	3.3
	No	24,285	96.7
Multimorbidity	Yes	3,247	12.9
	No	21,864	87.1

279 Comprises of Any White Background, Gypsy or Irish Traveller.

²Comprises of Bangladeshi, Pakistani, Indian, Any Other Asian Background. 280

³Comprises of Any Other Mixed Background, White and Asian, White and Black African, White and Black Caribbean, Any 281 282

Other Mixed/Multiple Ethnic Background.

⁴Comprises of African, Any Other Black Background, Caribbean 283

⁵Comprises of Any Other Ethnic Group, Arab, Chinese. 284

Examining time to vaccination in pregnancy 285

286 Kaplan-Meier survival analysis indicates that pregnant women living with 287 multimorbidity had a median time to vaccine uptake of 114 days (95% CI 106.6 to 288 121.4). This was lower than those with absence of multimorbidity, which had a 289 median time to vaccine uptake of 126 days (95% CI 123.4 to 128.6). A Log Rank test 290 was conducted to determine if there were significant differences in the survival distributions of vaccine uptake times for the different groups. The survival 291 distributions were statistically significantly different, $X^{2}(1) = 5.4$, p=0.02 (Figure 2a). 292 293 However, other survival analyses were also conducted to estimate the time to medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283200; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

294 vaccination for depression, diabetes, asthma, and cardiovascular diseases 295 independently. The survival distributions were not significantly different with a significance level >0.05 between the different groups for all the diseases 296 297 (Supplementary Table 11). Current Smoker women had a median time to vaccine 298 uptake of 142 days (95% CI 132.6 to 151.4). This was longer than Never Smokers 299 and Former Smokers, which had median times to vaccine uptake of 124 days (95% 300 CI 120.9 to 127.1) and 129 days (95% CI 121.7 to 136.3) respectively. The survival distributions between smoking status groups were significantly different, $X^{2}(3)$ 301 302 =40.23, p<.001. These differences were significant between the Current Smoker vs. 303 the Never Smoker groups, $X^{2}(1) = 18$, p<.001, and the Former Smoker vs. the Never 304 Smoker group, $X^2(1)=4.74$, p=0.03. However, the survival distribution for groups 305 Current Smoker vs. Former Smoker was not significantly different, $X^{2}(1)=2.43$, 306 p=0.12 (Figure 2b).

Fig 2a. Time to vaccine uptake by Multimorbidity





It is made available under a CC-BY-NC-ND 4.0 International license .

Examining the impact of multimorbidity, smoking status, and demographics on vaccine uptake

309 Women who had depression were slightly but significantly more likely to have the 310 vaccine compared to those without depression (HR=1.08, 95% CI 1.03 to 1.14, 311 p=.002) (supplementary table 12). Diabetes, asthma, and cardiovascular diseases 312 were not associated with vaccine uptakes (p>0.05 for all) (Supplementary Tables 13-313 15). Results indicate that women living with multimorbidity were 1.12 times more 314 likely to have the vaccine compared to those with no multimorbidity (HR=1.12, 95% 315 CI 1.04 to 1.19, p=.001). Vaccine uptakes were significantly lower among both 316 Current Smokers and Former Smokers compared to Never Smokers (HR=.87, 95% 317 CI .81 to .94, p<.001) and (HR=.92, 95% CI .85 to .98, p=.015) respectively. Those 318 aged 40-50 were 1.33 times more likely to have the vaccine compared to those aged 319 25-29 (HR=1.33, 95% CI 1.18 to 1.49, p<.001), also those aged 30-39 were 1.17 320 times more likely to have the vaccine compared to those aged 25-29 (HR=1.17, 95%) 321 CI 1.12 to 1.24, p<.001). It was also observed that the vaccine uptake was lower 322 among those living in the most deprived areas compared to those living in the most 323 affluent areas (HR=.89, 95% CI 0.83 to 0.96, p=.002). (Table 2).

Table 2. Cox Regression analysis of factors associated with vaccination uptake among
 pregnant women eligible for vaccination, adjusted analysis.

Characteristic		HR ¹ (95% Cl ²)	<i>P</i> value ³
Age group	25-29	Reference	
	18-24	.99 (0.92 – 1.07)	.788
	30-39	1.17 (1.12 – 1.24)	<.001
	40-50	1.33 (1.18 – 1.49)	<.001
Ethnic groups	White	Reference	

It is made available under a CC-BY-NC-ND 4.0 International license .

	Asian	1.09 (.97 – 1.22)	.140
	Mixed	1.02 (.81 – 1.28)	.899
	Black	1.06 (.87 – 1.29)	.577
	Other	1.16 (1.00 – 1.33)	.050
	Unknown	.94 (.87 – 1.01)	.067
WIMD quintile 2019	5 th (Least deprived)	Reference	
	4 th	.90 (.84 – .97)	.005
	3 rd	.82 (.76 – .88)	<.001
	2 nd	.92 (0.85 – 0.99)	.018
	1 st (Most deprived)	.89 (0.83 – 0.96)	.002
Smoking status	Never Smoker	Reference	
	Former Smoker	.92 (.8598)	.015
	Current Smoker	.87 (.8194)	<.001
	Unknown	1.09 (1.03 - 1.15)	.003
Multimorbidity	No Multimorbidity	Reference	
	Multimorbidity	1.12 (1.04 - 1.19)	.001
	· · · · · · · · · · · · · · · · · · ·		

¹Hazard Ratio, ²Confidence Interval (95%), ³significance level accepted at <0.05

327 Internal validation

328 The model was internally validated to estimate its performance more accurately. 329 Bootstrap resampling started with fitting the regression model in a bootstrap sample 330 of 1000 random samples, which were generated with replacement from the original 331 dataset. Bootstrapping analyses were performed on each random sample, and beta 332 coefficient, standard error, and 95% Bias corrected accelerated (BCa) confidence 333 intervals for the primary findings were generated. Bootstrapping estimated the 334 internal validity, providing stable estimates with low bootstrapped bias, low standard 335 errors, and robust confidence intervals for both the multimorbidity and depression 336 models (Table 3, supplementary table 16 respectively).

It is made available under a CC-BY-NC-ND 4.0 International license .

Characteristic		B ¹ (BCa 95% Cl ²)	Bias	Std. Error ³	<i>P</i> value ⁴
Age group	18-24	01 (08 – .07)	.000	.037	.784
	30-39	.06 (.11 – .22)	.001	.026	<.001
	40-50	.28 (.16 – .40)	.001	.059	<.001
Ethnic group	Asian	.09 (04 – .19)	.001	.059	.149
	Mixed	.02 (24 – .24)	006	.120	.901
	Black	.06 (15 –.24)	005	.098	.595
	Other	.14 (003 – .28)	001	.072	.044
	Unknown	07 (13 – .01)	.002	.036	.063
WIMD quintile 2019	4 th	11 (18 –35)	.001	.036	.005
	3 rd	20 (28 –13)	.000	.038	<.001
	2 nd	09 (16 –01)	.000	.037	.022
	1 st (Most deprived)	12 (19 –04)	.000	.036	.<.001
Smoking status	Former Smoker	08 (17 –02)	001	.04	.018
	Current Smoker	14 (21 –06)	001	.04	<.001
	Unknown	.09 (.033 – .14)	001	.03	.003
Multimorbiditv	Multimorbidity	.11 (.04 – .17)	001	.03	<.001

Table 3. Bootstrapping internal validation of factors associated with vaccination uptakeamong pregnant women eligible for vaccination

¹Bootstrapped Beta Coefficient, ²BCa Confidence Interval (95%), ³Standard Error, ⁴significance level accepted at <0.05

342 Discussion

This study investigated the impact of multimorbidity and smoking status on vaccine uptake as well as the impact of depression, diabetes, asthma, and cardiovascular diseases independently during pregnancy in Wales. Women with depression were slightly but significantly more likely to have the vaccine compared to those without depression. Those living with multimorbidity were also more likely to have the vaccine compared to those living with the absence of multimorbidity. Vaccine uptake was lower among those who currently smoke and those former smokers compared

³⁴¹

It is made available under a CC-BY-NC-ND 4.0 International license .

350 to those who have never smoked. Women aged 30 or older were more likely to have 351 the vaccine compared to younger women. Uptake was lower among those living in 352 the most deprived areas compared to those living in the most affluent areas. These 353 findings may help to generate and tailor vaccine strategies to the populations who 354 are more vaccine hesitant. The findings of the study complement previous studies of 355 vaccine hesitancy. The presence of one or more chronic conditions has been found 356 to be associated with the willingness to receive the COVID-19 vaccine [11]; this 357 study supported that those with multimorbidity are more likely to accept the vaccine 358 than non-multimorbid individuals. In previous studies, current smokers reported 359 significantly greater mistrust of vaccines and any benefits and were more worried 360 about future outcomes [13]. Current smokers were more likely to be unwilling to have 361 the vaccine; 21.5% compared to 11.6% of never smokers, (OR=2.12, 95% CI 1.91-362 2.34, p<.001) and compared to 14.7% of former smokers (OR=1.53, 95% CI 1.37-363 1.71, p<.001) [13]. The findings of the study also indicated that current and former 364 smokers were less likely to accept the COVID-19 vaccine. The 'Understanding 365 Society' COVID-19 survey asked participants (n = 12,035) their likelihood of vaccine 366 uptake and reason for hesitancy. Vaccine hesitancy was high in Black (71.8%) (OR= 367 13.42, 95% CI 6.86-26.24, p=<.05) and Pakistani/Bangladeshi (42.3%) OR=2.54, 368 95% CI 1.19-5.44, p=<.05 ethnic groups (compared to White British/Irish) [15]. The 369 results indicate that those living in more deprived areas in Wales were less likely to 370 accept the vaccine. Similar results were found with adults living in the most deprived 371 areas of England (based on the Index of Multiple Deprivation) were more likely to 372 report vaccine hesitancy (8%) than adults living in the least deprived areas (2%) [16].

It is made available under a CC-BY-NC-ND 4.0 International license .

373 Strengths and limitations

374 The study has several strengths; it utilises primary and secondary health care data 375 for pregnant women in Wales including the maternity and child health data, it gives a 376 national perspective of COVID-19 vaccine hesitancy, making the findings 377 generalizable due to its total population cohort. Bootstrapping internal validation was 378 performed to estimate the performance of the models with increased accuracy. The 379 study had some limitations, such as not indicating in which trimester pregnant 380 women had the vaccine: it has been reported that pregnant women in the first 381 trimester expressed higher acceptance of COVID-19 vaccination than those in the 382 second and third trimesters [14]. The study excluded miscarriage and stillbirth 383 outcomes as these are classed by SAIL as sensitive data and are not currently 384 accessible for research purposes.

385 Conclusion

In conclusion, it is critical to develop tailored strategies to increase the acceptance rates of the COVID-19 vaccine and decrease hesitancy. A more targeted approach to vaccinations may need to be addressed to reach certain groups such as younger people, smokers, healthy individuals, and those living in higher deprivation level areas. Encouraging vulnerable populations including pregnant women is a priority moving forward.

392 List of abbreviations

- 393 EHR: Electronic Health Records
- 394 SAIL: Secure Anonymised Information Linkage
- 395 HR: Hazard Ratios

It is made available under a CC-BY-NC-ND 4.0 International license .

- 396 SAGE: The Scientific Advisory Group for Emergencies
- 397 JCVI: The UK's Joint Committee on Vaccination and Immunisation
- 398 GP: General Practitioners
- 399 WLGP: Wales Longitudinal General Practice
- 400 PEDW: Patient Episode Database for Wales
- 401 OPDW: Outpatient Database for Wales
- 402 NCCH: National Community Child Health
- 403 MIDS: Maternal Indicators Dataset
- 404 CVVD: COVID-19 Vaccination Data
- 405 WDSD: Welsh Demographic Service Dataset
- 406 WIMD: Welsh Index for Multiple Deprivation
- 407 MD: Median Times
- 408 SQL: Structured Query Language
- 409 SPSS: Statistical Package for Social Sciences
- 410 WHO: The World Health Organisation
- 411 IGRP: Information Governance Review Panel
- 412 HDR: Health Data Research
- 413 BHF: British Heart Foundation
- 414 UK: United Kingdom

415 **Declarations**

- 416 Ethical approval and consent to participate
- 417 The data held in the SAIL (Secure Anonymised Information Linkage) Databank in
- 418 Wales/UK are anonymised. All data contained in SAIL has the permission from the

It is made available under a CC-BY-NC-ND 4.0 International license .

relevant Caldicott Guardian or Data Protection Officer and SAIL-related projects are
required to obtain Information Governance Review Panel (IGRP) approval. The
IGRP approval number for this study is 0911. The Research Ethics Service approval
was also given by the North West Greater Manchester East Research Ethics
Committee for the qualitative research. The Ethics Reference Number is RIO 03020.

425 Consent for publication

426 Not applicable

427 Availability of data and materials

The data that support the findings of this study are available from SAIL, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of SAIL.

432 Competing interests

433 The authors declare that they have no competing interests.

434 Funding

This work was funded by the National Core Studies, an initiative funded by UKRI, NIHR and the Health and Safety Executive. The COVID-19 Longitudinal Health and Wellbeing National Core Study was funded by the Medical Research Council (MC_PC_20030). SVK acknowledges funding from a NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17).

It is made available under a CC-BY-NC-ND 4.0 International license .

441 Authors' Contributions

- 442 SB, MM, HJ, and JK conceived the article. MM carried out the quantitative analysis.
- 443 MM and HJ prepared the first draft of the manuscript. MS, MP, NK, AA, LZ, ALA, AD,
- 444 KN contributed substantially to the manuscript, writing reviewing & editing. All
- 445 authors approved the final version submitted for publication

446 Acknowledgments

447 This study is part of the National Centre for Population Health and Wellbeing, which

is funded by Health Care Research Wales. This study makes use of anonymised

data held in the Secure Anonymised Information Linkage (SAIL) Databank (17, 20,

450 21). We would like to acknowledge all the data providers who make anonymised

451 data available for research.

452 This work was supported by Health Data Research UK, which receives its funding

453 from HDR UK Ltd (HDR-9006) funded by the UK Medical Research Council,

454 Engineering and Physical Sciences Research Council, Economic and Social

455 Research Council, Department of Health and Social Care (England), Chief Scientist

456 Office of the Scottish Government Health and Social Care Directorates, Health and

457 Social Care Research and Development Division (Welsh Government), Public Health

458 Agency (Northern Ireland), British Heart Foundation (BHF) and the Welcome Trust.

459 This work was supported by the ADR Wales programme of work. The ADR Wales

460 programme of work is aligned to the priority themes as identified in the Welsh

461 Government's national strategy: Prosperity for All. ADR Wales brings together data

462 science experts at Swansea University Medical School, staff from the Wales Institute

463 of Social and Economic Research, Data and Methods (WISERD) at Cardiff

464 University and specialist teams within the Welsh Government to develop new

It is made available under a C	C-BY-NC-ND 4.0	International license .
--------------------------------	----------------	-------------------------

465	evidence which supports Prosperity for All by using the SAIL Databank at Swansea
466	University, to link and analyse anonymised data. ADR Wales is part of the Economic
467	and Social Research Council (part of UK Research and Innovation) funded ADR UK
468	(grant ES/S007393/1).

- 469 This work was additionally supported by funding from the Data and Connectivity
- 470 National Core Study, led by Health Data Research UK in partnership with the Office
- 471 for National Statistics and funded by UK Research and Innovation (grant ref
- 472 MC_PC_20058), with additional support by The Alan Turing Institute via 'Towards
- 473 Turing 2.0' EPSRC Grant Funding.
- The responsibility for the interpretation of the information supplied is the authors'alone.

476 **References**

- 477 1 McClure CC, Cataldi JR, O'Leary ST. Vaccine Hesitancy: Where We Are and Where We
- 478 Are Going. Clin. Ther. 2017;39(8): 1550-1562.
- 479 2 Salomoni MG, Di Valerio Z, Gabrielli E et al. Hesitant or not hesitant? A systematic review
- 480 on global covid-19 vaccine acceptance in different populations. Vaccines. 2021;9(8).
- 481 3 Shook LL, Kishkovich TP, Edlow AG. Countering COVID-19 Vaccine Hesitancy in
- 482 Pregnancy: The 4 Cs. Am. J. Perinatol. 2021.
- 483 4 Hsu AL, Johnson T, Phillips L et al. Sources of Vaccine Hesitancy: Pregnancy, Infertility,
- 484 Minority Concerns, and General Skepticism.Open Forum Infect. Dis. 2021; 9(3).
- 485 5 M. Mhereeg, H. Jones, J. Kennedy, M. Seaborne, M. Parker, N. Kennedy, S. Beeson, A.
- 486 Akbari, L. Zuccolo, A. Davies and S. Brophy, "COVID-19 vaccination in pregnancy: views

medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283200; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 487 and vaccination uptake rates in pregnancy, a mixed methods analysis from the Born In
- 488 Wales study," Research Square, 2022.
- 489 6 Stock SJ, Carruthers J, Calvert C et al. SARS-CoV-2 infection and COVID-19
- 490 vaccination rates in pregnant women in Scotland. Nat. Med. 2022;28;504-512
- 491 7 GOV.UK Coronavirus (COVID-19) in the UK. Vaccination in England. Available from:
- 492 Vaccinations in England | Coronavirus in the UK (data.gov.uk). (Accessed 25 May 2022).
- 493 8 NICE (National Institute for health and care excellence). Available from Multimorbidity
- 494 Health topics A to Z | CKS | NICE. last revised in May 2018. (Accessed 30th September
- 495 2022)
- 496 9 NICE guidelines [NG22]. Available from Context | Older people with social care needs and
- 497 <u>multiple long-term conditions | Guidance | NICE</u>. Published: 04 November 2015. (Accessed
- 498 30th September 2022).
- 499 10 Filippetti, M.L., Clarke, A.D.F. & Rigato, S. The mental health crisis of expectant women
- 500 in the UK: effects of the COVID-19 pandemic on prenatal mental health, antenatal
- attachment and social support. *BMC Pregnancy Childbirth* 22, 68 (2022).
- 502 https://doi.org/10.1186/s12884-022-04387-
- 503 11 Wake AD. The willingness to receive COVID-19 vaccine and its associated factors:
- 504 "Vaccination Refusal Could Prolong the War of This Pandemic" a systematic review. Risk
- 505 Manag Healthc Policy. (2021) 2021:2609–23. doi: 10.2147/RMHP.S311074
- 506 12 Bergmann M, Hannemann T-V, Bethmann A, Schumacher AT. Determinants of SARS-
- 507 CoV-2 vaccinations in the 50+ Population. SSRN Electron J. (2021). doi:
- 508 10.2139/ssrn.3938975

medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283200; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 509 13 Jackson S. E., Paul E., Brown J., Steptoe A., Fancourt D. Negative Vaccine Attitudes and
- 510 Intentions to Vaccinate Against Covid-19 in Relation to Smoking Status: A Population Survey
- 511 of UK Adults, Nicotine & Tobacco Research. 2021. 23(9),1623–1628,
- 512 https://doi.org/10.1093/ntr/ntab039
- 513 14 Monideepa B. Becerra M. B., & Becerra B. J. COVID-19 Vaccine Hesitancy among
- 514 Behavioral Risk Takers. Vaccines 2022, 10(5), 767;
- 515 ttps://doi.org/10.3390/vaccines10050767
- 516 15 Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M, Katikireddi SV,
- 517 Benzeval MJ. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal
- 518 study. Brain Behav Immun. 2021 May;94:41-50. doi: 10.1016/j.bbi.2021.03.008. Epub 2021
- 519 Mar 11. PMID: 33713824; PMCID: PMC7946541.
- 520 16 ONS. 2021. Coronavirus and vaccine hesitancy, Great Britain: 9 August 2021
- 521 17 Jones KH, Ford DV, Thompson S, Lyons RA. A Profile of the SAIL Databank on the UK
- 522 Secure Research Platform. IJPDS. 2019;4(2). https://doi.org/10.23889/IJPDS.V4I2.1134
- 523 18 Lyons RA, Ford DV, Moore L et al. Use of data linkage to measure the population health
- 624 effect of non-health-care interventions. Lancet. 2014;383(9927): 1517-1519.
- 19 Lyons RA, Jones KH, John G et al. The SAIL databank: Linking multiple health and social
 care datasets. BMC Medical Inform. Decis. Mak. 2009;9(1).
- 527 20 Rodgers SE, Demmler JC, Dsilva, R. Protecting health data privacy while using 528 residence-based environment and demographic data. Health Place. 2012;18(2):209-217.
- 529 21 Jones KH, Ford DV, Thompson S et al. A Profile of the SAIL Databank on the UK Secure
- 530 Research Platform. IJPDS. 2020; 4(2).

It is made available under a CC-BY-NC-ND 4.0 International license .

- 531 22 Atkinson M., Kennedy J., John A., Lewis K., Lyons R., Brophy S., . . . Akbari A. (2017).
- 532 Development of an algorithm for determining smoking status and behaviour over the life
- 533 course from UK electronic primary care records. BMC Medical Informatics and Decision
- 534 *Making*, *17*(1), . doi:10.1186/s12911-016-0400-6

535 Additional files

536 Supplementary Tables - Impact of Multimorbidity on COVID-19 Vaccine Hesitancy